This insulin-pump company’s stock is plunging, and executives say it’s because diabetics in U.S. can’t afford the technology

Tandem Diabetes Care Inc. shares plummeted more than 20% after the company reported earnings Wednesday, continuing a decline that has already cost the company two-thirds of its market value this year.